4ls2: Difference between revisions

Line 1:

'''~~Unreleased~~ structure'''

==Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A313==

~~The~~ entry ~~4ls2~~ is ~~ON HOLD~~ ~~until Paper Publication~~

== Structural highlights ==

<table><tr><td colspan='2'>[[4ls2]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LS2 OCA]. For a guided tour on the structure components use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LS2 FirstGlance].

~~Authors~~: ~~Zhu, L~~., Li, H., Ren, X., Zhu, J.

</td></tr><tr><td class="sblockLbl">[[Ligand|Ligands:]]</td><td class="sblockDat"><scene name='pdbligand=3XS:2-[(E)-{2-[4-(3-METHOXYPHENYL)-1,3-THIAZOL-2-YL]HYDRAZINYLIDENE}METHYL]BENZOIC+ACID'>3XS</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=FMN:FLAVIN+MONONUCLEOTIDE'>FMN</scene>, <scene name='pdbligand=ORO:OROTIC+ACID'>ORO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene>

<tr><td class="sblockLbl">[[Related_structure|Related:]]</td><td class="sblockDat">[[4ls0|4ls0]], [[4ls1|4ls1]]</td></tr>

~~Description~~: ~~Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A313~~

<tr><td class="sblockLbl">Activity:</td><td class="sblockDat">[http://en.wikipedia.org/wiki/Dihydroorotate_dehydrogenase_(quinone) Dihydroorotate dehydrogenase (quinone)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.5.2 1.3.5.2] </td></tr>

<tr><td class="sblockLbl">Resources:</td><td class="sblockDat">[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ls2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ls2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ls2 RCSB], [http://www.ebi.ac.uk/pdbsum/4ls2 PDBsum]</td></tr>

<table>

== Disease ==

[[http://www.uniprot.org/uniprot/PYRD_HUMAN PYRD_HUMAN]] Defects in DHODH are the cause of postaxial acrofacial dysostosis (POADS) [MIM:[http://omim.org/entry/263750 263750]]; also known as Miller syndrome. POADS is characterized by severe micrognathia, cleft lip and/or palate, hypoplasia or aplasia of the posterior elements of the limbs, coloboma of the eyelids and supernumerary nipples. POADS is a very rare disorder: only 2 multiplex families, each consisting of 2 affected siblings born to unaffected, nonconsanguineous parents, have been described among a total of around 30 reported cases.<ref>PMID:19915526</ref>

== Function ==

[[http://www.uniprot.org/uniprot/PYRD_HUMAN PYRD_HUMAN]] Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.

== References ==

__TOC__

</StructureSection>

[[Category: Li, H.]]

[[Category: Ren, X.]]

[[Category: Zhu, J.]]

[[Category: Zhu, L.]]

[[Category: Fmn binding]]

[[Category: Mitochondria inner membrane]]

[[Category: Oxidoreductase]]

[[Category: Oxidoreductase-oxidoreductase inhibitor complex]]

Navigation menu

Page actions

Page actions

Personal tools

Navigation

Search

Tools

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+==Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A313==
+<StructureSection load='4ls2' size='340' side='right' caption='[[4ls2]], [[Resolution|resolution]] 2.27&Aring;' scene=''>
-The entry 4ls2 is ON HOLD  until Paper Publication
+== Structural highlights ==
+<table><tr><td colspan='2'>[[4ls2]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4LS2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4LS2 FirstGlance]. <br>
-Authors: Zhu, L., Li, H., Ren, X., Zhu, J.
+</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=3XS:2-[(E)-{2-[4-(3-METHOXYPHENYL)-1,3-THIAZOL-2-YL]HYDRAZINYLIDENE}METHYL]BENZOIC+ACID'>3XS</scene>, <scene name='pdbligand=ACT:ACETATE+ION'>ACT</scene>, <scene name='pdbligand=FMN:FLAVIN+MONONUCLEOTIDE'>FMN</scene>, <scene name='pdbligand=ORO:OROTIC+ACID'>ORO</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene><br>
+<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ls0|4ls0]], [[4ls1|4ls1]]</td></tr>
-Description: Crystal structure of human dihydroorotate dehydrogenase (DHODH) with DH03A313
+<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Dihydroorotate_dehydrogenase_(quinone) Dihydroorotate dehydrogenase (quinone)], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.3.5.2 1.3.5.2] </span></td></tr>
+<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ls2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ls2 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ls2 RCSB], [http://www.ebi.ac.uk/pdbsum/4ls2 PDBsum]</span></td></tr>
+<table>
+== Disease ==
+[[http://www.uniprot.org/uniprot/PYRD_HUMAN PYRD_HUMAN]] Defects in DHODH are the cause of postaxial acrofacial dysostosis (POADS) [MIM:[http://omim.org/entry/263750 263750]]; also known as Miller syndrome. POADS is characterized by severe micrognathia, cleft lip and/or palate, hypoplasia or aplasia of the posterior elements of the limbs, coloboma of the eyelids and supernumerary nipples. POADS is a very rare disorder: only 2 multiplex families, each consisting of 2 affected siblings born to unaffected, nonconsanguineous parents, have been described among a total of around 30 reported cases.<ref>PMID:19915526</ref>
+== Function ==
+[[http://www.uniprot.org/uniprot/PYRD_HUMAN PYRD_HUMAN]] Catalyzes the conversion of dihydroorotate to orotate with quinone as electron acceptor.
+== References ==
+<references/>
+__TOC__
+</StructureSection>
+[[Category: Li, H.]]
+[[Category: Ren, X.]]
+[[Category: Zhu, J.]]
+[[Category: Zhu, L.]]
+[[Category: Fmn binding]]
+[[Category: Mitochondria inner membrane]]
+[[Category: Oxidoreductase]]
+[[Category: Oxidoreductase-oxidoreductase inhibitor complex]]